Show simple item record

dc.contributor.advisorMoi, Line Leonore Haugan
dc.contributor.advisorBusund, Lill-Tove Rasmussen
dc.contributor.authorDelgado, André Berli
dc.date.accessioned2021-04-23T11:31:35Z
dc.date.available2021-04-23T11:31:35Z
dc.date.issued2020-08-31
dc.description.abstractBackground: Breast cancer is the most commonly diagnosed cancer in women internationally, and the most common cause of cancer related death among women. There are many ways to classify breast cancer, and breast cancer can be divided into several subgroups depending on which classification system is used. Pathological reports of breast carcinoma not only depend on one of these systems but include histopathological classification, grade of the tumor, and immunohistochemical (IHC) parameters like estrogen receptor (ER), progesterone receptor (PR), HER2- and Ki67-status. With the development of microarrays, it is now possible to analyze the genes of the cells, and with gene expression profiling (GEP) we have been able to evaluate breast cancer prognosis based on the gene expression of the cancer cells. Different genetic signatures of breast cancer have been obtained through DNA microarray technology, RNA sequencing and bioinformatic models. Some of these signatures have been validated through clinical studies and been translated into commercial prognostic assays. Four such commercial prognostic assays are Oncotype DX, MammaPrint, EndoPredict and PAM5-ROR. Methods: A literature search were conducted on the databases Medline and Embase. The inclusion criteria of the search were based on the Population, Intervention, Comparison and Outcome (PICO) framework. The search included terms to identify studies assessing the prognostic or economic aspects of Oncotype DX, MammaPrint, EndoPredict or Prosigna. Out of a total of 290 identified studies, 5 were included in this thesis. Results: Through the systematic literature search only studies focusing on Oncotype DX were included. The litterateur search disclosed that the Oncotype DX recurrence score (RS) is significantly associated with worse prognosis. The Oncotype DX RS were associated with both overall survival, disease free survival and local recurrence. The literature search also disclosed that Oncotype DX may be cost effective, especially in the high-risk RS group, were chemotherapy seemed to be clearly cost-effective because of the gain of additional quality- adjusted life-years (QUALY) at a low cost. Conclusion: The findings of this thesis suggest that Oncotype DX have an independent prognostic significance and is significantly associated with survival and risk of recurrence and may be helpful to guide treatment. Studies also show that Oncotype DX may be a cost effective alternative when used to guide adjuvant chemotherapy treatment.en_US
dc.identifier.urihttps://hdl.handle.net/10037/21025
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2020 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.subject.courseIDMED-3950
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Generell patologi, patologisk anatomi: 719en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::General pathology, anatomical pathology: 719en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk molekylærbiologi: 711en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical molecular biology: 711en_US
dc.titleAdvantages and limitations of molecular genetic prognostic tests for breast cancer. A systematic literature reviewen_US
dc.typeMaster thesisen_US
dc.typeMastergradsoppgaveen_US


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)